RIBAVIRIN DOES NOT IMPACT HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS ON OMBITASVIR/ PARITAPREVIR /RITONAVIR AND DASABUVIR AT THE END OF 12-WEEK TREATMENT IN TREATMENT-NAIVE ADULTS WITH GENOTYPE 1A (GT1A) CHRONIC HEPATITIS C

被引：0
|
作者：
Liu, Y. [1 ]
Bernstein, D. [2 ]
Larsen, L. [1 ]
Luo, Y. [1 ]
Xie, Y. [1 ]
Juday, T. [1 ]
机构：
[1] AbbVie Inc, N Chicago, IL USA
[2] N Shore Univ Hosp, Manhasset, IL USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI30
引用
收藏
页码：A227 / A227
页数：1
相关论文
共 50 条
  • [41] Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
    Hezode, Christophe
    Asselah, Tarik
    Reddy, K. Rajender
    Hassanein, Tarek
    Berenguer, Marina
    Fleischer-Stepniewska, Katarzyna
    Marcellin, Patrick
    Hall, Coleen
    Schnell, Gretja
    Pilot-Matias, Tami
    Mobashery, Niloufar
    Redman, Rebecca
    Vilchez, Regis A.
    Pol, Stanislas
    LANCET, 2015, 385 (9986): : 2502 - 2509
  • [42] Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naive and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan
    Virabhak, Suchin
    Yasui, Kikuo
    Yamazaki, Kiyotaka
    Johnson, Scott
    Mitchell, Dominic
    Yuen, Cammy
    Samp, Jennifer C.
    Igarashi, Ataru
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1144 - 1156
  • [43] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
    Grebely, Jason
    Puoti, Massimo
    Wedemeyer, Heiner
    Cooper, Curtis
    Sulkowski, Mark S.
    Foster, Graham R.
    Berg, Thomas
    Villa, Erica
    Rodriguez-Perez, Federico
    Wyles, David L.
    Schnell, Gretja
    Alami, Negar N.
    Zhang, Zhenzhen
    Dumas, Emily
    Dore, Gregory J.
    OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (11):
  • [44] Sofosbuvir plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 or 3 infection in India
    Shah, S. R.
    Chowdhury, A.
    Mehta, R.
    Kapoor, D.
    Duseja, A.
    Koshy, A.
    Shukla, A.
    Sood, A.
    Madan, K.
    Sud, R.
    Nijhawan, S.
    Pawan, R.
    Prasad, M.
    Kersey, K.
    Jiang, D.
    Svarovskaia, E.
    Doehle, B.
    Kanwar, B.
    Subramanian, M.
    Acharya, S. K.
    Sarin, S.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (05) : 371 - 379
  • [45] RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection with Severe Renal Impairment or End-Stage Renal Disease
    Vierling, John M.
    Lawitz, Eric
    Reddy, K. Rajender
    Cohen, Eric
    Kemmer, Nyingi
    Morelli, Giuseppe
    Zamor, Philippe J.
    Bennett, Michael
    Bernstein, David E.
    Kowdley, Kris V.
    Mantry, Parvez S.
    Pockros, Paul J.
    Wyles, David L.
    Kumar, Sonal
    Bhamidimarri, Kalyan R.
    Cohen, Daniel E.
    Pilot-Matias, Tami
    Xie, Wangang
    Podsadecki, Thomas
    Hassanein, Tarek I.
    HEPATOLOGY, 2016, 64 : 441A - 441A
  • [46] Daily dosing regimen of consensus interferon and ribavirin for treatment-naive patients with chronic hepatitis C and genotype 1.
    Kaiser, S
    Hass, HG
    Gregor, M
    HEPATOLOGY, 2003, 38 (04) : 302A - 302A
  • [47] An exploratory study to evaluate immune restoration after removal of viral antigen in adults with genotype 1a chronic hepatitis C virus infection treated with ombitasvir/oparitaprevir/ritonavir plus dasabuvir and ribavirin for 12 weeks
    Carlton-Smith, C.
    Holmes, J. A.
    Kim, A. Y.
    Dumas, E. O.
    Brown, J.
    Alatrakchi, N.
    Lauer, G. M.
    Silva, S. T.
    Tonnerre, P.
    Cohen, D. E.
    Zhang, H.
    Shulman, N. S.
    Chung, R. T.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S732 - S733
  • [48] THE REAL-WORLD ISRAELI EXPERIENCE OF TREATING CHRONIC HEPATITIS C, GENOTYPE 1 PATIENTS WITH ADVANCED FIBROSIS WITH PARITAPREVIR/RITONAVIR/OMBITASVIR, DASABUVIR WITH OR WITHOUT RIBAVIRIN: A LARGE MULTI-CENTER COHORT
    Zuckerman, E.
    Ashkenasi, E.
    Kovalev, Y.
    Weitsman, E.
    Kaspa, R. T.
    Brown, M.
    Cohen, M.
    Saadi, T.
    Baruch, Y.
    Carlebach, M.
    Hazzan, R.
    Safadi, R.
    Goldberg, T.
    Oren, R.
    Ashur, Y.
    Carmiel, M.
    Kitay, Y.
    Hadari, R.
    Mouch, S. A.
    Menachem, Y.
    Kathcman, H.
    Bruk, R.
    Shibolet, O.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S137 - S137
  • [49] COST-EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR VERSUS OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR (3D REGIMEN) FOR TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1B PATIENTS IN CHINA
    Chen, P. Y.
    Liu, Q.
    Li, H. C.
    Ma, A. X.
    VALUE IN HEALTH, 2018, 21 : S64 - S64
  • [50] Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results
    Wei, L.
    Hou, J.
    Luo, Y.
    Heo, J.
    Chu, C. -J.
    Duan, Z.
    Cho, M.
    Cheng, J.
    Li, J.
    Jia, J.
    Lu, W.
    Fredrick, L. M.
    Pilot-Matias, T.
    Mobashery, N.
    Chuang, W. -L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S532 - S532
12345